Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иннейт ФармаfiledCriticalИннейт Фарма
Priority claimed from PCT/EP2018/081364external-prioritypatent/WO2019096900A1/en
Publication of EA202090551A1publicationCriticalpatent/EA202090551A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Настоящее изобретение относится к способам применения соединений, которые ингибируют ферментативную активность растворимого CD39 человека, при лечении рака для усиления активности агента или терапии, которые вызывают внеклеточное высвобождение АТФ из опухолевых клеток и/или гибель опухолевых клеток.The present invention relates to methods of using compounds that inhibit the enzymatic activity of human soluble CD39 in the treatment of cancer to enhance the activity of an agent or therapy that causes extracellular release of ATP from tumor cells and / or death of tumor cells.
EA202090551A2018-09-192018-11-15
ENHANCING THE EFFECT FROM RELEASE OF ADENOSINTRIPHOSPHATE (ATP)
EA202090551A1
(en)